Literature DB >> 9450757

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

K L Collins1, B K Chen, S A Kalams, B D Walker, D Baltimore.   

Abstract

Cytotoxic T lymphocytes (CTLs) lyse virally infected cells that display viral peptide epitopes in association with major histocompatibility complex (MHC) class I molecules on the cell surface. However, despite a strong CTL response directed against viral epitopes, untreated people infected with the human immunodeficiency virus (HIV-1) develop AIDS. To resolve this enigma, we have examined the ability of CTLs to recognize and kill infected primary T lymphocytes. We found that CTLs inefficiently lysed primary cells infected with HIV-1 if the viral nef gene product was expressed. Resistance of infected cells to CTL killing correlated with nef-mediated downregulation of MHC class I and could be overcome by adding an excess of the relevant HIV-1 epitope as soluble peptide. Thus, Nef protected infected cells by reducing the epitope density on their surface. This effect of nef may allow evasion of CTL lysis by HIV-1-infected cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9450757     DOI: 10.1038/34929

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  401 in total

1.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Mechanism for down-regulation of CD28 by Nef.

Authors:  T Swigut; N Shohdy; J Skowronski
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

3.  HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes.

Authors:  V Piguet; L Wan; C Borel; A Mangasarian; N Demaurex; G Thomas; D Trono
Journal:  Nat Cell Biol       Date:  2000-03       Impact factor: 28.824

Review 4.  Structure--function relationships in HIV-1 Nef.

Authors:  M Geyer; O T Fackler; B M Peterlin
Journal:  EMBO Rep       Date:  2001-07       Impact factor: 8.807

5.  HIV-1 Nef impairs MHC class II antigen presentation and surface expression.

Authors:  P Stumptner-Cuvelette; S Morchoisne; M Dugast; S Le Gall; G Raposo; O Schwartz; P Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

Authors:  J M Johnson; C Nicot; J Fullen; V Ciminale; L Casareto; J C Mulloy; S Jacobson; G Franchini
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation.

Authors:  S Le Gall; F Buseyne; A Trocha; B D Walker; J M Heard; O Schwartz
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Rebekah I Fleis; Chris G Przybycin; Kathleen L Collins
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.

Authors:  L J Cooper; M Kalos; D A Lewinsohn; S R Riddell; P D Greenberg
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

10.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.